Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1994 2
1995 2
1996 2
1997 2
1999 5
2000 1
2002 1
2003 1
2005 1
2006 2
2007 2
2009 3
2010 2
2011 4
2012 2
2013 3
2014 1
2015 2
2017 2
2018 2
2019 5
2020 3
2021 7
2022 8
2023 13
2024 10

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
Lorusso D, Mouret-Reynier MA, Harter P, Cropet C, Caballero C, Wolfrum-Ristau P, Satoh T, Vergote I, Parma G, Nøttrup TJ, Lebreton C, Fasching PA, Pisano C, Manso L, Bourgeois H, Runnebaum I, Zamagni C, Hardy-Bessard AC, Schnelzer A, Fabbro M, Schmalfeldt B, Berton D, Belau A, Lotz JP, Gropp-Meier M, Gladieff L, Lück HJ, Abadie-Lacourtoisie S, Pujade-Lauraine E, Ray-Coquard I. Lorusso D, et al. Among authors: parma g. Int J Gynecol Cancer. 2024 Apr 1;34(4):550-558. doi: 10.1136/ijgc-2023-004995. Int J Gynecol Cancer. 2024. PMID: 38129136 Free PMC article. Clinical Trial.
Association of location of BRCA1 and BRCA2 mutations with benefit from olaparib and bevacizumab maintenance in high-grade ovarian cancer: phase III PAOLA-1/ENGOT-ov25 trial subgroup exploratory analysis.
Labidi-Galy SI, Rodrigues M, Sandoval JL, Kurtz JE, Heitz F, Mosconi AM, Romero I, Denison U, Nagao S, Vergote I, Parma G, Nøttrup TJ, Rouleau E, Garnier G, El-Balat A, Zamagni C, Martín-Lorente C, Pujade-Lauraine E, Fiévet A, Ray-Coquard IL. Labidi-Galy SI, et al. Among authors: parma g. Ann Oncol. 2023 Feb;34(2):152-162. doi: 10.1016/j.annonc.2022.11.003. Epub 2022 Nov 28. Ann Oncol. 2023. PMID: 36564284 Free article.
Ovarian cancer.
Colombo N, Van Gorp T, Parma G, Amant F, Gatta G, Sessa C, Vergote I. Colombo N, et al. Among authors: parma g. Crit Rev Oncol Hematol. 2006 Nov;60(2):159-79. doi: 10.1016/j.critrevonc.2006.03.004. Epub 2006 Oct 2. Crit Rev Oncol Hematol. 2006. PMID: 17018256 Review.
Myeloid neoplasms post PARP inhibitors for ovarian cancer.
Caruso G, Gigli F, Parma G, Lapresa M, Derio S, Palaia I, Colombo N. Caruso G, et al. Among authors: parma g. Int J Gynecol Cancer. 2023 Apr 3;33(4):598-606. doi: 10.1136/ijgc-2022-004190. Int J Gynecol Cancer. 2023. PMID: 36707087 Review.
Neoadjuvant chemotherapy in cervical cancer: an update.
Lapresa M, Parma G, Portuesi R, Colombo N. Lapresa M, et al. Among authors: parma g. Expert Rev Anticancer Ther. 2015;15(10):1171-81. doi: 10.1586/14737140.2015.1079777. Epub 2015 Sep 7. Expert Rev Anticancer Ther. 2015. PMID: 26402247 Review.
Management of ovarian stromal cell tumors.
Colombo N, Parma G, Zanagnolo V, Insinga A. Colombo N, et al. Among authors: parma g. J Clin Oncol. 2007 Jul 10;25(20):2944-51. doi: 10.1200/JCO.2007.11.1005. J Clin Oncol. 2007. PMID: 17617526 Review.
Atezolizumab and chemotherapy for advanced or recurrent endometrial cancer (AtTEnd): a randomised, double-blind, placebo-controlled, phase 3 trial.
Colombo N, Biagioli E, Harano K, Galli F, Hudson E, Antill Y, Choi CH, Rabaglio M, Marmé F, Marth C, Parma G, Fariñas-Madrid L, Nishio S, Allan K, Lee YC, Piovano E, Pardo B, Nakagawa S, McQueen J, Zamagni C, Manso L, Takehara K, Tasca G, Ferrero A, Tognon G, Lissoni AA, Petrella M, Laudani ME, Rulli E, Uggeri S, Barretina Ginesta MP; AtTEnd study group. Colombo N, et al. Among authors: parma g. Lancet Oncol. 2024 Sep;25(9):1135-1146. doi: 10.1016/S1470-2045(24)00334-6. Epub 2024 Aug 2. Lancet Oncol. 2024. PMID: 39102832 Clinical Trial.
Role of chemotherapy in relapsed ovarian cancer.
Colombo N, Parma G, Bocciolone L, Sideri M, Franchi D, Maggioni A. Colombo N, et al. Among authors: parma g. Crit Rev Oncol Hematol. 1999 Dec;32(3):221-8. doi: 10.1016/s1040-8428(99)00049-9. Crit Rev Oncol Hematol. 1999. PMID: 10633851 Review. No abstract available.
Epidemiology of COVID-19 Among Indigenous Populations in Brazil.
da Silva MG, Pereira PMB, Portela WF, Daros GC, Barbosa CRA, Vanassi BM, Parma GOC, de Bitencourt RM, Iser BPM. da Silva MG, et al. Among authors: parma goc. J Racial Ethn Health Disparities. 2022 Jun;9(3):960-966. doi: 10.1007/s40615-021-01035-2. Epub 2021 Apr 12. J Racial Ethn Health Disparities. 2022. PMID: 33844167 Free PMC article.
78 results